CompletedNot Applicable

Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)

Germany647 participantsStarted 2017-01-25

Plain-language summary

A safety and efficacy study of first line therapy with Vectibix® in combination with FOLFIRI or FOLFOX to validate a prognostic score in adult patients with RAS wild-type metastatic colorectal cancer in a real world setting (VALIDATE)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Eligibility according to current SmPC * Signed written informed consent * Diagnosis of RAS-WT mCRC * No prior systemic therapy in the palliative setting * Aged 18 years or older Exclusion Criteria: * Any contraindication according to current SmPC * Participation in other clinical trials

What they're measuring

Overall Survival (OS) of pre-defined risk groups low vs. high

Timeframe: From date of start of first line therapy to date of death due to any cause (assessed up to 84 months)

Trial details

NCT IDNCT03043950

SponsoriOMEDICO AG

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-01-17

View on ClinicalTrials.gov More Metastatic Colorectal Cancer trials